Assessing the utility of CTC count-driven therapy in breast cancer [Video]

Jean-Yves Pierga, MD, Institut Curie, Paris, France, provides an overview of the emerging role of circulating tumor cells (CTC) as a method of determining therapies in patients with breast cancer. For patients with a high circulating tumor cell count, hormonal treatment is recommended in the first-line HR+/HER2- setting. Additional research is underway to determine whether circulating tumor cell count can be useful in the second-line setting. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.